Polymyxin B3 sulfate is an individual fraction found in the antibiotic mixture polymyxin B sulfate. Polymyxin B3 sulfate is differentiated from its counterpart fractions by the presence of an octanoic fatty acid moiety. Results from in vitro studies have shown marginal differences in MIC data when comparing the fractions.
We also offer:
- Polymyxin B Sulfate, USP (P007)
- Polymyxin B1 Sulfate, EvoPure® (P037)
- Polymyxin B1-I Sulfate, EvoPure® (P038)
- Polymyxin B2 Sulfate, EvoPure® (P039)
- Polymyxin B6 Sulfate, EvoPure® (P054)
- Polymyxin E1 Sulfate, EvoPure® (P055)
- Polymyxin E2 Sulfate, EvoPure® (P056)
EvoPure® products are purified single antibiotic fractions, most are >99% pure. Highly pure EvoPure® Polymyxin products can be used to analyze the specifc effects of individual Polymyxin B fractions.
|Mechanism of Action||Polymyxin B targets and alters permeability lipopolysaccharide (LPS) of gram negative bacteria leading to lysing of the cell. Polymyxin B only needs to interact with LPS, it is not required to enter the cell.|
|Spectrum||Polymyxin B Sulfate targets the outer membrane of gram negative bacteria especially Pseudomonas aeruginosa.
Kassamali, et al. found Polymyxin B3 to be the most active polymyxin fraction against most organisms in their experiment. Kassamali, et al. also discovered a synergistic effect using Polymyxin B3 and B1-I against their tested organisms.
|Microbiology Applications||Polymyxin B Sulfate is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include:
|Plant Biology Applications||Polymyxin B Sulfate was successfully tested to counteract phytopathogenic Gram-negative bacterial growth including different strains of Pseudomonas viridiflava and Erwinia carotovora. Polymixin B Sulfate was shown to reduce bacterial growth of different strains of Pseudomonas viridiflava at low concentrations, (0.08 µg/ml) and Erwinia carotovora growth at slightly higher concentrations (0.25 µg/ml) (Selim et al. 2005).|
|Molecular Formula||C55H96N16O13 · xH2O4S (lot specific)|
Kassamali, et al. used polymyxin B1, polymyxin B2, polymyxin B3, and polymyxin B1-I to test for synergistic and antagonistic effects against various Gram-negative organisms in:
Newton BA (1956) The properties and mode of action of the Polymyxins. Bacter. Rev. 20(1):14-27 PMID 13303920
Selim S, Negrel J, Govaerts C, Gianinazzi S and Tuinen van D (2005) Isolation and partial characterization of antagonistic peptides produced by Paenibacillus sp. strain B2 isolated from the sorghum Mycorrhizosphere. Appl. Environ. Microbiol. 71(11):6501–6507 PMID 16269674
Zavascki AP, Goldani LA, Li J and Nation RL (2007) Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J. Antimicrob. Chemother. 60(6):1206-1215 PMID 17878146
Cao G et al (2009) Development and validation of a reversed-phase high-performance liquid chromatography assay for Polymyxin B in human plasma. J. Antimicrob. Chemother. 62(5):1009-1014 PMID 18765414
Tam VH, Cao H, Ledesma, KR, Hu M (2011) In vitro potency of various Polymyxin B components.55(9):4490-491 PMID 21709096
Orwa JA et al (2001) Isolation and structural characterization of Polymyxin B components. J Chromatogr A 912(2):369-373 PMID 11330807
Mueller MJ, Brodschelm W, Spannagl E and Zenk MH (1993) Signaling in the elicitation process is mediated through the octadecanoid pathway leading to jasmonic acid. Proc. Natl. Acad. Sci. USA 90(16):7490-7494 PMID 11607420
|MIC||P. aeruginosa (ATCC 27853)| 1 |1666| A. baumannii (ATCC BAA 747)|1|1666| K. pneumoniae ATCC 13883|1|1666| P. aeruginosa (9019)|0.5|1666| A. baumannii (1261)|0.5|1666| K. pneumoniae (VM9)|0.5|1666||